BlackRock Fund Advisors’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

BlackRock Fund Advisors’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,105,516	Closed	-$23.1M	–	4306
2016 Q3	$23.1M	Buy	1,105,516 +55,163	+5%	+$635K	﹤0.01%	1997
2016 Q2	$11.3M	Buy	1,050,353 +419,667	+67%	+$3.59M	﹤0.01%	2340
2016 Q1	$4.18M	Buy	630,686 +17,220	+3%	+$157K	﹤0.01%	2836
2015 Q4	$11.1M	Buy	613,466 +270,351	+79%	+$3.72M	﹤0.01%	2383
2015 Q3	$3.78M	Sell	343,115 -2,842	-0.8%	-$30.2K	﹤0.01%	2938
2015 Q2	$4.98M	Buy	345,957 +165,148	+91%	+$2.24M	﹤0.01%	2925
2015 Q1	$2.12M	Buy	+180,809	New	+$2.44M	﹤0.01%	3116

BlackRock Fund Advisors's VTAE Position: Q4 2016 in Review

BlackRock Fund Advisors sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 1,105,516 shares — an estimated $23.1M sold.

BlackRock Fund Advisors first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $23.1M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

BlackRock Fund Advisors reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
BlackRock Fund Advisors sold 1,105,516 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $23.1M.
BlackRock Fund Advisors first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
BlackRock Fund Advisors's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $23.1M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.